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 What ’ s known on the subject? and What does the study add? 
 Largest survey ever conducted evaluating the management of AUR in real life practice 
in a wide range of health care systems. It shows that urethral catheterization followed 
by a TWOC has become a standard worldwide and that  α 1 -blockade prior to TWOC 
doubles the chances of success. It also evidences important differences (hospitalization 
rate, duration of catheterization  . . . ) between countries/regions refl ecting lack of 
guidelines. This large survey also clearly identifi es predictors of TWOC failure. 
 OBJECTIVES 
 •  To evaluate the management of acute 
urinary retention (AUR) associated with 
benign prostatic hyperplasia (BPH) in 
real-life practice. 
 •  To identify predictors of successful trial 
without catheter (TWOC). 
 MATERIALS AND METHODS 
 •  In all, 6074 men catheterized for painful 
AUR were enrolled in a prospective, 
cross-sectional survey conducted in public 
and private urology practices in France, 
Asia, Latin America, Algeria and the Middle 
East. 
 •  Patient clinical characteristics, type of 
AUR and its management (type of 
catheterization, hospitalization, TWOC, use 
of  α 1 -blockers, immediate or elective 
surgery) and adverse events observed 
during the catheterization period were 
recorded. 
 •  Predictors of TWOC success were also 
analysed by multivariate regression analysis 
with stepwise procedure. 
 RESULTS 
 •  Of the 6074 men, 4289 (71%) had a 
spontaneous AUR and 1785 (29%) had a 
precipitated AUR, mainly as the result of 
loco-regional/general anaesthesia (28.5%) 
and excessive alcohol intake (18.2%). 
 •  Presence of BPH was revealed by AUR in 
44% of men. Hospitalization for AUR 
varied between countries, ranging from 
1.7% in Algeria to 100% in France. A 
urethral catheter was inserted in most 
cases (89.8%) usually followed by a TWOC 
(78.0%) after a median of 5 days. Overall 
TWOC success rate was 61%. 
 •  Most men (86%) received an  α 1 -blocker 
(mainly alfuzosin) before catheter removal 
with consistently higher TWOC success 
rates, regardless of age and type of AUR. 
Multivariate regression analysis confi rmed 
that  α 1 -blocker before TWOC doubled the 
chances of success (odds ratio 1.92, 95% CI 
1.52 – 2.42,  P  <  0.001 ). 
 •  Age  ≥ 70 years, prostate size  ≥ 50  g, 
severe lower urinary tract symptoms, 
drained volume at catheterization 
 ≥ 1000  mL and spontaneous AUR favoured 
TWOC failure. Catheterization  > 3 days did 
not infl uence TWOC success but was 
associated with increased morbidity and 
prolonged hospitalization for adverse 
events. 
 •  In the case of TWOC failure, 49% of men 
were recatheterized and had BPH surgery 
and 43.5% tried another TWOC with a 
success rate of 29.5%. Elective surgery was 
preferred to immediate surgery. 
 CONCLUSIONS 
 •  TWOC has become a standard practice 
worldwide for men with BPH and AUR. 
 •  In most cases, an  α 1 -blocker is 
prescribed before TWOC and signifi cantly 
increases the chance of success. 
 •  Prolonged catheterization is associated 
with an increased morbidity. 
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 INTRODUCTION 
 Acute urinary retention (AUR) is a severe 
complication of BPH characterized by a 
sudden and painful inability to void 
voluntarily  [ 1 ] . It is a distressing condition 
 [ 2 ] that represents a major public health 
issue. Within the last decade, AUR has 
become the most common indication for 
TURP, increasing from 22.9% in 1988 to 
42.9% in 1998  [ 3 ] . In addition, a recent 
analysis of 176  046 men admitted to NHS 
hospitals in England for AUR between 1998 
and 2005 has shown that mortality within 
the year after a fi rst AUR episode was much 
higher than in the general population, 
especially in younger patients  [ 4 ] . 
 In clinical practice, AUR is usually attributed 
to BPH, as being part of its natural history 
(so-called  ‘ spontaneous AUR ’ ). Data from 
large community-based longitudinal studies 
have identifi ed old age, severe lower urinary 
tract symptoms (LUTS), low peak fl ow rate, 
high postvoid residual urine (PVR), enlarged 
prostate and high serum PSA as signifi cant 
risk factors for spontaneous AUR  [ 5,6 ] . 
Dynamic variables such as symptom 
worsening and increasing PVR during 
medical therapy are also powerful predictors 
of AUR  [ 7,8 ] . In other cases, AUR develops 
after a precipitating event other than BPH 
(so-called  ‘ precipitated ’ AUR), for example a 
surgical procedure with general or loco-
regional anaesthesia, bladder overdistension, 
urinary tract infection, medications with 
sympathomimetic or anticholinergic effects 
 [ 9 ] . The differentiation between both types 
of AUR is relevant in clinical practice 
because precipitated AUR is associated with 
a much higher mortality rate at 1 year 
(24-fold increase vs general population) 
than spontaneous AUR (10-fold increase) 
 [ 4 ] . This is possibly explained by a higher 
prevalence of severe underlying comorbid 
conditions in men with precipitated AUR 
and this may have important implications in 
terms of AUR management. 
 Management of AUR consists of immediate 
bladder decompression by catheterization 
usually followed by BPH-related surgery. 
The evidence that emergency surgery was 
associated with an increased mortality 
rate at 30 days and a higher rate of 
postoperative complications, and the 
potential morbidity associated with 
prolonged catheterization have led to an 
increasing use of a trial without catheter 
(TWOC)  [ 9,10 ] . A TWOC involves catheter 
removal, usually after 2 – 3 days of  α 1 -
blockade, allowing the patient to return to 
normal voiding in up to 60% of cases 
 [ 10,11 ] . The benefi t of  α 1 -blockade on the 
TWOC success rate was shown in a large 
double-blind, placebo-controlled study that 
randomized 360 men with AUR to alfuzosin 
10  mg once daily or placebo for 2 – 3 days 
followed by a TWOC  [ 11 ] . It was further 
established by a recent Cochrane 
metaanalysis  [ 12 ] . This TWOC policy is likely 
to have contributed to the decrease in the 
number of TURPs after a fi rst AUR episode 
in the UK but balanced against this is a 
slight increase in the AUR recurrence rate 
 [ 13 ] . 
 Nevertheless, there is currently no consensus 
on the optimal management of AUR, in 
terms of type of catheterization, duration of 
catheterization and management after 
catheterization. The Reten-World survey 
aimed to evaluate prospectively the current 
practice in management of AUR associated 
with BPH, in various regions (France, Latin 
America, Asia, Algeria, Middle East) 
representing a wide range of healthcare 
systems. 
 METHODS 
 In all, 6074 men presenting with a painful 
AUR related to BPH were enrolled between 
April 2004 and April 2008 by 953 urologists 
from public (37%), private (42%) or mixed 
(21%) healthcare practices in a prospective 
cross-sectional survey conducted in France 
( n  =  2618), Asia (Korea, Pakistan, Philippines, 
Taiwan, Thailand, Vietnam;  n  =  1727), Latin 
America (Colombia, Mexico, Venezuela; 
 n  =  883), Algeria ( n  =  755) and the Middle 
East (Bahrain, Qatar, Kuwait, United Arab 
Emirates;  n  =  91). The results of the French 
survey have already been published  [ 14 ] . 
Patient demographic data, history of BPH, 
prostate size estimated by DRE, type of AUR 
(spontaneous or precipitated), amount of 
drained volume, management of AUR (type 
and duration of catheterization, TWOC, use 
of  α 1 -blockers before TWOC, hospitalization 
rate, immediate or elective surgery) and 
adverse events observed during the 
catheterization period were recorded. 
Written informed consent was obtained 
from all patients. Study protocol was 
approved by the ethics committees and 
Health Authorities, according to local 
legislation. 
 Statistical comparisons were made using 
chi-squared or Fisher exact test for 
qualitative variables and Student ’ s  t test for 
quantitative variables. A  P value  <  0.05 
was considered statistically signifi cant. A 
multiple logistic regression analysis with 
stepwise procedure was performed to 
determine whether the TWOC success rate 
was infl uenced by selected variables (age 
 < 70 or  ≥ 70 years, LUTS severity according 
to International Prostate Symptom Score, 
prostate size  ≤ 50 or  > 50  mL, catheterization 
for  ≤ 3 or  > 3 days, drained volume at 
catheterization  < 1000 or  ≥ 1000  mL, 
 α 1 -blockade before TWOC). The calculations 
were performed using the Statistical 
Analysis System (version 9.1.3; SAS Institute 
Inc. Cary, NC, USA). 
 RESULTS 
 Of the 6074 men enrolled, 4289 (70.6%) 
had a spontaneous AUR and 1785 (29.4%) 
had a precipitated AUR. Patient clinical 
characteristics are provided globally and by 
region in  Table  1 . Algeria showed the lowest 
rate of precipitated AUR (11.9%) whereas 
Latin America showed the highest rate 
(43.8%), mainly consecutive to excessive 
alcohol intake ( Fig.  1 ). Another important 
triggering event for AUR was surgery with 
loco-regional/general anaesthesia, especially 
in France. A previous AUR episode was 
reported by 16.5% of men, ranging from 
10% in France to 24% in the Middle East, 
within a median delay of 7 months before 
enrolment. Compared with spontaneous 
AURs, precipitated AURs were characterized 
by signifi cantly less severe LUTS (22.3% vs 
31.7%,  P  <  0.001), a lower percentage of 
prostate glands  > 50  g (36.9% vs 45.4%, 
 P  <  0.001) and a higher rate of BPH revealed 
by AUR (44.2% vs 32.9%,  P  <  0.001). 
 Catheterization was performed almost 
exclusively by urologists in France (81.3%) 
but it was performed by an emergency room 
physician in up to 40.9% of patients in 
other regions ( Table  2 ). A urethral catheter 
was inserted in most cases (89.8%), 
whatever the region. France showed the 
highest rate of suprapubic catheter insertion 
(16.7%). The hospitalization rate for AUR 
varied between regions, ranging from 1.7% 
in Algeria to 100% in France. 
 After initial catheterization, TWOC was the 
standard whatever the region (76.8%) 
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 TABLE  1  Clinical characteristics of 6074 men catheterized for painful acute urinary retention 
Total
 ( N  =  6074)
France
 ( N  =  2618)
Asia
 ( N  =  1727)
Latin America
 ( N  =  883)
Algeria
 ( N  =  755)
Middle East
 ( N  =  91)
Age, years
  Median 70 72 70 68 72 65
  < 65, % 27.4 26.0 26.2 37.0 20.5 49.4
  65 – 74, % 39.3 37.6 41.6 37.6 42.1 38.5
  ≥ 75, % 33.3 36.4 32.2 25.4 37.4 12.1
Type of AUR, %
  Spontaneous 70.6 71.6 68.8 56.2 88.1 71.4
  Precipitated 29.4 28.4 31.2 43.8 11.9 28.6
BPH revealed by AUR, %
  Yes 36.2 33.2 37.6 39.5 40.1 30.8
  No 63.8 66.8 62.4 60.5 59.9 69.2
Severity of LUTS * , %
  Mild 13.3 16.8 7.6 14.8 13.6 14.3
  Moderate 57.5 61.3 51.8 57.2 56.9 75.0
  Severe 29.2 21.9 40.6 27.9 29.6 10.7
DRE estimated prostate size † , g
  < 30, % 6.5 6.1 11.3 3.7 0.3 3.3
  30 – 50, % 50.4 44.6 60.3 50.2 43.3 36.3
  > 50, % 43.1 49.3 28.4 46.1 56.4 60.4
History of previous AUR
  Yes, % 16.5 10.2 23.6 19.6 18.0 24.2
  Median delay, months 6.9 7.2 7.5 7.9 4.5 8.4
 * Available in 3874 men. Lower urinary tract symptom severity evaluated according to International Prostate Symptom Score.  † Available in 5013 men. AUR, 
acute urinary retention; BPH, benign prostatic hyperplasia; DRE, digital rectal examination; LUTS, lower urinary tract symptoms. 
 FIG.  1.  
Triggering event in 
1785 men catheterized 
for a precipitated acute 
urinary retention. UTI, 
urinary tract infection. 
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( Table  2 ), with slightly higher rates for 
precipitated AURs compared with 
spontaneous AURs (86.1% vs 73% 
respectively,  P  <  0.001). Overall, 13.3% of 
men were managed by prolonged 
catheterization followed by programmed 
surgery, the highest rates being reported in 
France (17.9%) and Latin America (15.1%). 
Immediate surgery was less common (7.2%), 
the highest rate being reported in Asia 
(12.9%) and the lowest in Algeria (0.5%). 
Compared with precipitated AURs, 
spontaneous AURs were more likely to be 
treated by surgery, either immediately (8.4% 
vs 4.3%,  P  <  0.001) or after prolonged 
catheterization (15.6% vs 7.6%,  P  <  0.001). 
 In all, 4667 men underwent a fi rst TWOC 
with an overall success rate of 61.4% 
(precipitated AUR 66.3%, spontaneous AUR 
59.0%,  P  <  0.001). Median duration of 
catheterization before TWOC ranged from 3 
days in France to 8 days in Algeria. Most 
men (85.9%) received an  α 1 -blocker before 
the TWOC (alfuzosin 68.2%, tamsulosin 
16.5%, doxazosin 6.1%, terazosin 2.6%, 
prazosin 0.1%). Use of an  α 1 -blocker before 
TWOC signifi cantly increased overall the 
success rate (63.4% vs 49.5%,  P  <  0.001), 
including for spontaneous (61.4% vs 44.5%, 
 P  <  0.001) and precipitated (67.5% vs 
59.0%,  P  =  0.01) AURs. Similarly, the benefi t 
of  α 1 -blockade before TWOC was confi rmed 
irrespective of age ( Fig.  2 ). 
 Univariate regression analysis showed that 
older age ( ≥ 70 years), enlarged prostates 
( > 50  g), severe LUTS, large drained volume 
at catheterization ( ≥ 1000  mL) and AUR of 
spontaneous origin were associated with 
signifi cantly higher rates of TWOC failure 
whereas catheterization for  > 3 days and 
 α 1 -blockade before TWOC increased success 
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rates ( Fig.  3 ). Multivariate analysis with 
a stepwise procedure confi rmed the 
predictive value of these variables on 
TWOC outcome except for catheterization 
duration  > 3 days, which was no more 
 TABLE  2  Initial management of acute urinary retention (AUR) in 6074 men catheterized for painful AUR 
Total
 ( N  =  6074)
France
 ( N  =  2618)
Asia
 ( N  =  1727)
Latin America
 ( N  =  883)
Algeria
 ( N  =  755)
Middle East
 ( N  =  91)
Type of practice, %
  Public 37.4 33.1 85.7 16.9 83.3 40.0
  Private 41.9 54.9 1.0 22.3 16.7 10.0
  Both 20.7 12.0 13.3 60.8 0 50.0
Type of catheter, %
  Urethral 89.8 82.7 94.5 98.1 93.1 95.6
  Suprapubic 8.2 16.7 1.8 1.0 2.3 3.3
  In and out 1.8 0 3.7 0.9 4.6 1.1
  Unspecifi ed 0.3 0.6 0 0 0 0
Catheterization performed by, %
  Urologist 60.5 81.3 36.5 59.0 50.1 63.7
  Emergency room physician 21.1 0.4 35.8 30.6 40.9 33.0
  Nurse 15.3 17.3 21.5 8.4 4.4 1.1
  Other 3.2 1.0 6.1 2.0 4.6 2.2
Drained volume, %
  < 1000  mL 68.4 63.2 72.6 67.7 77.0 75.8
  ≥ 1000  mL 31.6 36.8 27.4 32.3 23.0 24.2
Hospitalization for AUR
  Yes, % 57.4 100.0 40.4 12.6 1.7 52.7
Management after catheterization
  TWOC 76.8 72.8 75.4 75.8 93.6 91.2
  Immediate surgery 7.2 5.7 12.9 6.5 0.5 4.4
  Prolonged catheter and elective 
surgery
13.3 17.9 9.4 15.1 5.0 4.4
  Stent 0.2 0.4 0.1 0 0 0
  Indwelling catheter 1.6 1.1 2.4 2.6 0.5 0
  Unspecifi ed 1.1 2.1 0 0.2 0.3 0
 TWOC, trial without catheter. 
 FIG.  2. 
Impact of  α 1 -blockade 
on trial without 
catheter (TWOC) 
success rate by age. 
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signifi cant. Allowing for all these factors, 
 α 1 -blocker before a TWOC still doubled 
the chances of successful TWOC (odds 
ratio 1.92, 95% CI 1.52 – 2.42,  P  <  0.001) 
( Table  3 ) . 
 Of the 2862 men with successful fi rst TWOC, 
most (86.7%) continued on  α 1 -blockade 
(alone 76.1% or combined either with a 
5 α -reductase inhibitor, 8.4%, or a plant 
extract, 2.2%) while being followed up 
regularly ( Table  4 ). In all, 5.7% had 
programmed surgery whatever the outcome 
(spontaneous AUR 6.0%, precipitated AUR 
5.2%,  P  =  ns) whereas 19.7% would have 
surgery performed if needed (precipitated 
AUR 13.0%, spontaneous AUR 23.3%, 
 P  <  0.001). 
 Of the 1798 men who failed a fi rst TWOC, 
most (49%) were recatheterized and 
underwent BPH-related surgery whereas 
43.5% tried another TWOC after a median of 
8 days after the catheterization . The second 
TWOC was successful in 29.5% of cases 
(precipitated AUR 34.0%, spontaneous AUR 
27.5%,  P  =  0.07), ranging from 19.7% in 
Algeria to 44.1% in Asia ( Table  4 ;  Fig.  4 ). Of 
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Odds ratio (95% CI)  P value
Age (median)
  < 70 years 1  < 0.001
  ≥ 70 years 0.73 (0.62 – 0.86)
Type of AUR
  Precipitated 1  < 0.001
  Spontaneous 0.70 (0.58 – 0.70)
Amount of drained volume
  < 1000  mL 1  < 0.001
  ≥ 1000  mL 0.62 (0.51 – 0.74)
 α 1 -blocker before TWOC
  No 1  < 0.001
  Yes 1.92 (1.52 – 2.42)
LUTS severity before AUR
  Mild 1 0.51
 < 0.001  Moderate 0.93 (0.73 – 1.17)
  Severe 0.61 (0.47 – 0.80)
Prostate volume
  ≤ 50  g 1  < 0.001
  > 50  g 0.63 (0.53 – 0.74)
 TABLE  3  
Predictors of trial without 
catheter success rate 
(multiple logistic regression 
analysis) 
 AUR, acute urinary 
retention; 95% CI, 95% 
confi dence interval; LUTS, 
lower tract urinary 
symptoms; TWOC, trial 
without catheter. 
 FIG.  3.  Signifi cant predictors of trial without catheter (TWOC) success in univariate analysis. P, precipitated 
acute urinary retention (AUR); S, spontaneous AUR; IPSS, International Prostate Symptom Score; catheter 
duration is expressed in days. 
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the 542 men who failed a second TWOC, 
70.7% were recatheterized and had surgery, 
18.8% tried a third TWOC with an overall 
success rate of 26.4% and 10.5% had 
another approach. 
 Catheterization for more than 3 days was 
associated with a signifi cantly higher rate 
of adverse events compared with those 
catheterized for 3 days or less (33.8% vs 
19.7%,  P  <  0.001) ( Table  5 ). In patients who 
were hospitalized, prolonged catheterization 
also resulted in a slightly higher rate of 
prolonged hospitalization for adverse events 
(5.2% vs 3.5%,  P  =  0.007). 
 DISCUSSION 
 Acute urinary retention represents the 
commonest indication for BPH-related 
surgery  [ 3 ] but its management is still not 
standardized because of a lack of existing 
guidelines. The cross-sectional survey 
described here evaluates prospectively the 
management of AUR in a wide range of 
healthcare systems. The key fi ndings may 
be summarized as follows. First, initial 
management of AUR mainly consists of 
urethral catheterization followed by TWOC 
but important differences exist between 
countries regarding hospitalization rate, 
duration of catheterization and management 
of TWOC outcome. Second, it confi rms in 
real-life practice that older age, severe LUTS, 
large drained volume at catheterization and 
AUR of spontaneous origin favour TWOC 
failure. Nevertheless, considering all these 
factors,  α 1 -blockade before a TWOC still 
doubles the chances of success. Third, 
prolonged catheterization ( > 3 days) does 
not infl uence TWOC outcome in multivariate 
analysis but is associated with a greater 
comorbidity and a prolonged hospitalization 
rate because of adverse events. Fourth, 
if the fi rst TWOC fails, another TWOC 
may be attempted with a success rate of 
29.5%. Last, only a few men (one in four) 
undergoes BPH-related surgery after a fi rst 
episode of AUR, elective surgery being 
preferred to immediate surgery. 
 Before discussing the policy implications of 
the survey, some methodological aspects 
should be considered. There was no random 
selection of participating centres, which 
raises the question if they were fully 
representative of standard of care in a 
given country. Our survey is the largest 
ever conducted in this setting and was 
specifi cally designed to include at least 50% 
of urology centres in each country, both in 
public and private practice. In our opinion, it 
provides the physician with reliable and 
useful information on AUR management in 
a given country. It also allows comparison of 
daily practices to a wide range of healthcare 
systems, showing not only common trends 
between countries but also important 
differences, which need to be addressed to 
optimize patient care. 
 In this survey, the hospitalization rate for 
AUR varied between countries, ranging 
from 1.7% in Algeria to 100% in France. 
This obviously refl ects major differences 
between healthcare systems but it also 
questions the necessity of hospitalizing men 
presenting with AUR. In a UK survey, 65.5% 
of physicians automatically admitted men 
catheterized for AUR whereas 19.3% would 
only admit those with renal impairment  [ 10 ] . 
According to the UK National Prostatectomy 
Audit, men discharged home after 
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 TABLE  4  Management in case of TWOC 
Total
 ( N  =  4667)
France
 ( N  =  1906)
Asia
 ( N  =  1302)
Latin America
 ( N  =  669)
Algeria
 ( N  =  707)
Middle East
 ( N  =  83)
Duration of catheterization before a fi rst TWOC, days
  Median 5 3 6 6 8 7
  ≤ 3 days, % 41.3 65.2 30.8 24.6 19.5 20.7
  > 3 days, % 58.7 34.8 69.2 75.4 80.5 79.3
 α 1 -blockade before TWOC * 
  Yes, % 85.9 79.0 89.5 85.1 97.7 92.8
First TWOC ( n )
  Success rate, % 61.4 50.2 66.0 75.2 69.0 71.1
Outcome if fi rst TWOC is a success † 
  Medical treatment, % 88.8 76.8 94.8 89.3 99.6 98.3
  Surgery whatever the outcome, % 5.7 8.5 3.1 9.3 1.4 1.7
  Surveillance and surgery if needed, % 19.7 24.8 4.5 5.0 53.1 5.1
  Other, % 3.4 0.4 0.7 0 0 0
Outcome if fi rst TWOC fails
  Recatheterize and try a second TWOC 43.5 33.4 42.8 45.8 85.8 54.2
  Recatheterize and plan surgery 49.0 57.5 48.9 51.2 12.8 33.3
  Stent 0.9 1.5 0 0 0 12.5
  Long-term catheter 2.8 1.1 7.2 3.0 1.8 0
  Other 3.5 6.1 1.1 0 0 0
Second TWOC ( n ) (782) (316) (189) (76) (188) (13)
  Success rate, % 29.5 25.9 44.1 30.7 19.7 38.5
Outcome if second TWOC is a success † 
  Medical treatment, % 88.8 77.2 97.6 82.6 100 100
  Surgery whatever the outcome, % 5.7 7.6 3.1 9.3 1.4 1.7
  Surveillance and surgery if needed, % 19.7 24.8 4.5 5.0 53.1 5.1
  Other, % 3.4 0.4 0.7 0 0 0
Outcome if second TWOC fails
  Recatheterize and try a third TWOC 18.8 6.2 39.0 26.9 21.2 12.5
  Recatheterize and plan surgery 70.7 77.0 51.4 67.3 74.8 87.5
  Stent 1.7 4.0 0 0 0 0
  Long-term catheter 7.0 8.0 10.5 5.8 4.0 0
  Other 3.3 6.2 2.9 1.9 0 0
Third TWOC ( n ) (102) (14) (41) (14) (32) (1)
  Success rate, % 26.4 NR 32.5 21.4 18.8 100
 * Alfuzosin 68.2%, tamsulosin 16.5%, doxazosin 6.1%, terazosin 2.6%, prazosin 0.1%.  † Sum is higher than 100% because several options may be ticked.NR, 
not reported, TWOC, trial without catheter. 
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catheterization to await surgery showed a 
higher rate of uncomplicated urinary tract 
infection and consequently received more 
antibiotics than those kept in hospital 
but there was no increased risk of major 
infective complications  [ 15,16 ] . Nevertheless, 
cost savings of sending the patient home 
should be balanced against patient 
discomfort and anxiety generated by the 
catheter being  in situ outside the hospital. 
 The survey also establishes TWOC as 
standard practice worldwide (76.8%) in 
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 TABLE  5  Impact of catheter duration of the adverse event profi le 
 ≤ 3 days 
( n  =  1853), 
 n (%)
 > 3 days 
( n  =  2638), 
 n (%)  P value
At least one adverse event during catheter period 281 (19.7) 1453 (33.8)  < 0.001
Haematuria 177 (9.6) 274 (10.4) 0.35
Asymptomatic bacteriuria 81 (5.7) 579 (13.5)  < 0.001
Lower urinary tract infection 49 (3.4) 308 (7.2)  < 0.001
Urosepsis 9 (0.6) 51 (1.2) 0.06
Urine leak 52 (3.7) 297 (6.9)  < 0.001
Catheter obstruction 12 (0.8) 133 (3.1)  < 0.001
Other adverse events 14 (1.0) 72 (1.7) 0.05
Prolongation of hospitalization for adverse event 47 (3.5) 209 (5.2) 0.007
men catheterized for AUR, with an overall 
success rate of 61%. The advantage of 
TWOC is that it allows BPH-related surgery 
to be performed later, and without the 
morbidity associated with a catheter. 
According to the UK National Prostatectomy 
Audit, deferred surgery for AUR is associated 
with signifi cantly reduced risks of 
perioperative complications and 
postoperative death at 30 days  [ 15 ] . This 
 ‘ window of opportunity ’ possibly allows 
patients, who are usually elderly with 
comorbid conditions, to face surgery in 
 ‘ fi tter condition ’ with a better detrusor 
function. Our results are in agreement 
with those of a UK survey conducted 
among 410 consultant urologists  [ 10 ] 
showing that most of them (73.9%) were 
using TWOC, mainly after 2 days 
catheterization (48.5%). 
 The large database collected here (4667 men 
with TWOC), allowed us to conduct a robust 
analysis of predictors of TWOC outcome. 
Multivariate analysis identifi ed older age 
( ≥ 70 years), large prostates ( ≥ 50  g), 
severe LUTS, large drained volume at 
catheterization ( ≥ 1000  mL) and AUR of 
spontaneous type as predictors of TWOC 
failure. Nevertheless, even in the presence of 
these adverse factors,  α 1 -blockade before 
TWOC almost doubled the chances of 
success. This is in agreement with the 
ALFAUR (Alfuzosin in Acute Urinary 
Retention) study, which also reported a 
higher rate of failed TWOC in men age  ≥ 65 
years or with a drained volume  ≥ 1000  mL 
and a twice as high chance of success in 
men treated with alfuzosin within the 2 – 3 
days before TWOC  [ 11 ] . The benefi t of 
 α 1 -blockade before TWOC was further 
established by a Cochrane metaanalysis of 
fi ve randomized trials, including four with 
alfuzosin  [ 12 ] . It confi rms an old concept, 
which was initially suggested by Caine  et  al . 
in 1976  [ 17 ] , that AUR is the consequence 
of a sudden sympathetic stimulation causing 
an acute increase in smooth muscle tone in 
the lower urinary tract. By relaxing the 
smooth muscle tone,  α 1 -blockers would 
then favour a return to normal voiding. 
 It has been reported that chances of 
successful TWOC increase with the 
duration of catheterization  [ 18 ] . Our 
survey also showed in a univariate 
analysis that catheterization for  > 3 days 
was associated with higher TWOC success 
rates. Nevertheless, in multivariate analysis, 
duration of catheterization before TWOC 
was no more signifi cant. In our opinion, 
considering the fact that longer catheter 
duration signifi cantly increases the risk 
of complications such as urinary tract 
infections, urine leak and catheter 
obstruction, all efforts should be made 
to try to minimize the duration of 
catheterization and so reduce comorbidity 
and healthcare costs. 
 When the fi rst TWOC was successful, 
5.7% of patients had deferred surgery 
irrespective of the outcome whereas 
19.7% would undergo surgery only if 
needed. Although fi gures appear slightly 
higher for spontaneous AURs compared 
with precipitated AURs, these results show 
that a fi rst episode of AUR is not an 
absolute indication for surgery and that 
deferred surgery  ‘ if needed ’ is the preferred 
option among urologists worldwide. In the 
second phase of the ALFAUR study, which 
randomized patients with successful TWOC 
to alfuzosin 10  mg once daily or placebo for 
6 months, BPH-related surgery was needed 
in 17.1% of patients treated with alfuzosin 
vs 24.1% of patients receiving placebo, 
mainly because of AUR relapse  [ 19 ] . A 
retrospective analysis of 165  527 men 
admitted for AUR between 1998 and 2003 
in NHS hospitals revealed that BPH-related 
surgery after a fi rst episode of AUR tended 
to decrease over time, being required in 
32% of men with spontaneous AUR and 
5.8% of men with precipitated AUR in 
2003  [ 13 ] . Conversely, the percentage of 
patients readmitted for AUR relapse slightly 
increased over the same period. These data 
emphasize the need to evaluate carefully 
the risk of unfavourable outcome after 
TWOC to identify patients who may benefi t 
from a prolonged medical therapy without 
developing complications and those who 
need to undergo surgery in the short-term. 
In our survey, enlarged prostates, severe 
LUTS, large drained volume and AUR of 
spontaneous origin were associated with 
an increased risk of TWOC failure. These 
variables have also been identifi ed as 
predictors of recurrent AUR/surgery after 
a successful TWOC  [ 9,18,20 ] . They could be 
used to select patients who should rapidly 
be offered a surgical procedure. 
 In conclusion, this large cross-sectional 
survey, which enrolled 6074 men with BPH 
catheterized for AUR, evaluates prospectively 
the management of this urological 
emergency in a wide range of healthcare 
systems. It shows that urethral 
catheterization followed by a TWOC is the 
standard practice worldwide and that 
 α 1 -blockade before TWOC doubles the 
chances of success. Nevertheless, it also 
highlights important differences between 
countries regarding hospitalization rate, 
duration of catheterization and management 
of TWOC outcome, which are attributed to 
lack of guidelines for AUR management. 
Multivariate analysis of predictors of TWOC 
outcome reveal that catheterization for  > 3 
days does not infl uence the success rate but 
is associated with a greater comorbidity and 
prolonged hospitalization for adverse events. 
Older age, severe LUTS, large drained volume 
at catheterization and AUR of spontaneous 
origin favour TWOC failure. As these 
variables also predict the risk of recurrent 
AUR/surgery after a successful TWOC, they 
could be used to identify the subgroup of 
patients that cannot be managed by medical 
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therapy alone and should rapidly undergo 
surgery. 
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